UG Healthcare (8K7.SI, SES) pre-market: earnings due 11 Feb 2026 could shift price

We open pre-market on 07 Feb 2026 with 8K7.SI stock at S$0.093, and UG Healthcare’s upcoming earnings on 11 Feb 2026 is the immediate catalyst. Volume has been active at 643,500 shares today, above the 30-day average. Investors should watch margin drivers and inventory turns; recent metrics show negative EPS and thin margins that could steer short-term moves. This earnings report may change the market’s view on valuation and supply-demand for Unigloves products in Singapore and global markets.

8K7.SI stock: Earnings calendar and expectations

UG Healthcare (8K7.SI) reports earnings on 11 Feb 2026. The company scheduled disclosure is the near-term event likely to affect pre-market trading on the Singapore Exchange (SES). Analysts will focus on revenue mix between latex and nitrile gloves and any commentary on order book and pricing.

Expect questions on margins and inventory. Recent operating metrics show long days-of-inventory at 215.09 days, which can amplify margin pressure if demand weakens.

Recent financials and valuation snapshot

At S$0.093, market cap is roughly S$58.02 million. Trailing EPS is -0.01 and the reported PE is -9.30, reflecting recent losses. Price-to-book sits near 0.37, and price-to-sales is 0.41, signaling low market expectations versus book value.

Liquidity shows a current ratio of 2.70, but free cash flow per share is negative at -0.01. Investors should weigh a modest balance sheet against weak cash conversion and negative EPS.

Operational metrics, risks and near-term drivers

Key operational red flags include long receivables at 120.14 days and inventory turnover of 1.70 times. These extend the cash conversion cycle to 249.17 days and increase working capital needs.

Risks for 8K7.SI stock include commodity price swings for raw materials and order volatility from healthcare customers. Upside drivers include stronger export demand or improved nitrile glove margins.

Technical setup and trading data for traders

Pre-market price is trading below the 50-day and 200-day averages (both ~S$0.10). RSI is 38.17, indicating weak momentum but not a full oversold condition. Average daily volume is 557,642; today’s volume 643,500 is 1.15x relative activity.

Short-term traders should note Bollinger band middle at S$0.10 and day range S$0.09–S$0.09 to S$0.094, which caps upside until earnings clarity arrives.

Meyka AI rates 8K7.SI with a score out of 100

Meyka AI rates 8K7.SI with a score out of 100: Score 64.57 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s model flags mixed signals: valuation metrics (PB 0.37) look cheap, but cash flow and profitability are weak. Use the grade as one data point; it is not investment advice.

Forecasts, price targets and sector comparison

Meyka AI’s forecast model projects a yearly target of S$0.10 and a monthly near-term level of S$0.10, with a quarterly conservative scenario at S$0.07. Compared with current price S$0.093, the yearly projection implies roughly 12.63% upside.

Healthcare peers trade at higher multiples (sector average PE around 22.18) and stronger margins, highlighting valuation dispersion and sector risk for small-cap glove makers.

Final Thoughts

Earnings on 11 Feb 2026 are the most relevant near-term event for 8K7.SI stock; investors should watch margin commentary, inventory guidance, and order trends. At S$0.093, UG Healthcare shows cheap valuation signals such as PB 0.37 and P/S 0.41, but negative EPS and weak cash flow remain material concerns. Meyka AI’s forecast model projects a yearly target of S$0.10, implying ~12.63% upside versus the current price S$0.093, while a conservative short-term scenario could take price to S$0.07 if margins deteriorate. Our Meyka grade (Score 64.57, Grade B, Suggestion: HOLD) balances cheap book valuation against operational headwinds. Use earnings results to re-assess risk-reward, with stop-loss discipline given volatility and liquidity levels on SES. Forecasts are model-based projections and not guarantees; always cross-check disclosures on the company site and official filings. For quick reference, see UG Healthcare’s site and our Meyka page for live updates and data company site Meyka stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.